BYL719
Total Payments
$3.1M
Transactions
267
Doctors
63
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $45,883 | 10 | 5 |
| 2019 | $84,140 | 79 | 26 |
| 2017 | $3.0M | 178 | 38 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.9M | 140 | 95.6% |
| Consulting Fee | $124,323 | 43 | 4.0% |
| Travel and Lodging | $6,239 | 24 | 0.2% |
| Food and Beverage | $4,377 | 57 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,845 | 3 | 0.1% |
Payments by Type
Research
$2.9M
140 transactions
General
$136,783
127 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| SOLAR1 A PHASE III RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ALPELISIB IN COMBINATION WITH FULVESTRANT FOR MEN AND POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHICH PROGRESSED ON OR AFTER AROMATASE INHIBITOR TREATMENT | Novartis Pharmaceuticals Corporation | $1.2M | 0 |
| A PHASE II RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF LETROZOLE WITH OR WITHOUT BYL719 OR BUPARLISIB FOR THE NEOADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE BREAST CANCER | Novartis Pharmaceuticals Corporation | $383,082 | 0 |
| A PHASE IB DOSE FINDING STUDY OF BYL719 PLUS EVEROLIMUS AND BYL719 PLUS EVEROLIMUS PLUS EXEMESTANE IN PATIENTS WITH ADVANCED SOLID TUMORS WITH DOSE EXPANSION COHORTS IN RENAL CELL CANCER RCC PANCREATIC NEUROENDOCRINETUMORS PNETS AND ADVANCED BREAST CANCER BC PATIENTS | Novartis Pharmaceuticals Corporation | $230,097 | 0 |
| A PHASE IA MULTICENTER OPEN LABEL DOSE ESCALATION STUDY OF ORAL BYL719 IN ADULT PATIENTS WITH ADVANCED SOLID MALIGNANCIES WHOSE TUMORS HAVE AN ALTERATION OF THE PIK3CA GENE | Novartis Pharmaceuticals Corporation | $207,123 | 0 |
| A PHASE IB STUDY OF CISPLATIN PLUS BYL719 IN HPV ASSOCIATED TUMORS | Novartis Pharmaceuticals Corporation | $160,541 | 0 |
| A PHASE 1 OPEN LABEL SINGLE DOSE MULTICENTER PARALLEL GROUP STUDY TO ASSESS THE PHARMACOKINETICS AND SAFETY OF ALPELISIB BYL719 IN SUBJECTS WITH HEPATIC IMPAIRMENT COMPARED TO MATCHED HEALTHY CONTROL SUBJECTS | Novartis Pharmaceuticals Corporation | $159,295 | 0 |
| A PHASE IB DOSE ESCALATION AND OR RANDOMIZED PHASE II MULTICENTER OPEN LABEL STUDY OF BYL719 IN COMBINATION WITH CETUXIMAB IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA | Novartis Pharmaceuticals Corporation | $127,544 | 0 |
| A PHASE II MULTICENTER OPEN LABEL TWO COHORT NON COMPARATIVE STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB PLUS FULVESTRANT OR LETROZOLE IN PATIENTS WITH PIK3CA MUTANT HORMONE RECEPTOR HR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER ABC WHO HAVE PROGRESSED ON OR AFTER CDK 4 6 INHIBITOR TREATMENT | Novartis Pharmaceuticals Corporation | $111,835 | 0 |
| A PHASE I AND OR II OPEN LABEL MULTI CENTER STUDY OF THE SAFETY AND EFFICACY OF BLZ945 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULTS PATIENTS WITH ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $81,269 | 0 |
| PHASE I AND OR II STUDY OF BYL719 PLUS ABRAXANE IN PATIENTS WITH LOCALLY RECURRENT OR METASTATIC TRIPLE NEGATIVE BREAST CANCER PI3K ABERRATIONS WILL BE PROSPECTIVELY CHARACTERIZED IN ALL PATIENTS | Novartis Pharmaceuticals Corporation | $68,378 | 0 |
| A PHASE 1 TRIAL WITH COHORT EXPANSION OF BYL719 IN COMBINATION WITH GEMCITABINE AND NAB PACLITAXEL IN LOCALLY ADVANCED AND METASTATIC PANCREATIC CANCER | Novartis Pharmaceuticals Corporation | $66,114 | 0 |
| A PHASE I STUDY OF CETUXIMAB PLUSBYL719 PLUSIMRT INTENSITY MODULATED RADIATION THERAPY IN STAGE III AND OR IVB HEAD AND NECK SQUAMOUS CELL CANCER HNSCC | Novartis Pharmaceuticals Corporation | $47,042 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $27,152 | 11 |
| A PHASE IB TRIAL OF BYL719 A CLASS I A SPECIFIC PI3K INHIBITOR IN COMBINATION WITH ENDOCRINE THERAPY IN POST MENOPAUSAL PATIENTS WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER | Novartis Pharmaceuticals Corporation | $19,839 | 0 |
| A PHASE IB AND OR II OPEN LABEL SINGLE ARM STUDY OF THE COMBINATION THERAPY OF BYL719 PLUS GANITUMAB IN ADULT PATIENTS WITH SOLID TUMORS HAVING MUTANT OR AMPLIFIED PIK3CA WHO HAVE PROGRESSED DESPITE PRIOR STANDARD TREATMENT | Novartis Pharmaceuticals Corporation | $18,360 | 0 |
| A PHASE I STUDY OF BYL719 AND TRASTUZUMAB MCC DM1 IN HER2 POSITIVE METASTATIC BREAST CANCER WHO PROGRESSED ON PRIOR TRASTUZUMAB BASED THERAPY | Novartis Pharmaceuticals Corporation | $17,560 | 0 |
| BYL719 CAPECITABINE AND RADIATION FOR RECTAL CANCER A BROWN UNIVERSITY ONCOLOGY RESEARCH GROUP PHASE I STUDY | Novartis Pharmaceuticals Corporation | $11,240 | 0 |
| PATIENTS WITH METASTATIC OR LOCALLY ADVANCED UNRESECTABLE HORMONE RECEPTOR POSITIVE BREAST CANCER WHO ARE BEING TREATED WITH OR PROGRESSED ON AROMATASE INHIBITOR AI THERAPY | Novartis Pharmaceuticals Corporation | $4,127 | 0 |
Top Doctors Receiving Payments for BYL719
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $2.9M | 125 |
| , M.D, PHD | Internal Medicine | Houston, TX | $21,557 | 1 |
| , MD | Dermatology | San Francisco, CA | $10,080 | 2 |
| , MD | Pediatric Hematology-Oncology | Boston, MA | $9,516 | 2 |
| , M.D | Diagnostic Radiology | Boston, MA | $9,347 | 2 |
| , M.D | Pediatric Hematology-Oncology | Cincinnati, OH | $8,540 | 2 |
| , MD | Medical Oncology | Dallas, TX | $8,450 | 7 |
| , M.D | Pediatrics | Rochester, MN | $8,400 | 2 |
| , MD | Medical Oncology | Nashville, TN | $7,040 | 4 |
| , M.D | Hematology & Oncology | Boston, MA | $6,639 | 7 |
| , M.D | Dermatopathology | Houston, TX | $6,515 | 5 |
| , MD | Specialist | West Hollywood, CA | $6,270 | 3 |
| , M.D | Dermatology | Chicago, IL | $6,038 | 6 |
| , MD | Medical Oncology | Lexington, MA | $5,618 | 8 |
| , M.D.,PH.D | Dermatology | Tampa, FL | $5,539 | 4 |
| , MD | Dermatology | New York, NY | $5,199 | 4 |
| , M.D | Internal Medicine | San Francisco, CA | $5,078 | 5 |
| , MD | Endocrinology, Diabetes & Metabolism | New York, NY | $3,675 | 4 |
| , MD | Medical Oncology | Kansas City, MO | $3,076 | 4 |
| , MB BCH BAO, MRCPI | Endocrinology, Diabetes & Metabolism | New York, NY | $3,043 | 3 |
| , M.D., PH.D | Medical Oncology | New York, NY | $2,451 | 3 |
| , M.D., PH.D | Student in an Organized Health Care Education/Training Program | New York, NY | $2,260 | 4 |
| , M.D | Hematology & Oncology | Westwood, KS | $2,089 | 2 |
| , MD | Internal Medicine | Boston, MA | $1,762 | 2 |
| , M.D | Medical Oncology | Chicago, IL | $1,717 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.1M
- Total Doctors 63
- Transactions 267
About BYL719
BYL719 is a drug associated with $3.1M in payments to 63 healthcare providers, recorded across 267 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $45,883 was paid across 10 transactions to 5 doctors.
The most common payment nature for BYL719 is "Unspecified" ($2.9M, 95.6% of total).
BYL719 is associated with 18 research studies, including "SOLAR1 A PHASE III RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ALPELISIB IN COMBINATION WITH FULVESTRANT FOR MEN AND POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER WHICH PROGRESSED ON OR AFTER AROMATASE INHIBITOR TREATMENT" ($1.2M).